Skip to main content
Clinical Trials/NCT07440797
NCT07440797
Not yet recruiting
Not Applicable

EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD: MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL

Laboratoires URGO1 site in 1 country102 target enrollmentStarted: March 1, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
102
Locations
1
Primary Endpoint
clinical success at week 4

Overview

Brief Summary

Evaluation of the efficacy (reduction of inflammatory signs suggesting a local infection) and tolerance (emergence and nature of adverse event) of Vashe solution vs Saline solution in the treatment of venous or mixed leg ulcers presenting inflammatory signs suggesting heavy bacterial load

Detailed Description

This study is carried out in United States of America in around 10 investigator sites. A total of 102 patients meeting the eligibility criteria will be included

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patient, at least 18 years of age or older who has provided free, written, and informed consent,
  • Patient who has already worn compression therapy in the past and agrees to wear the two-layer compression system during the whole treatment period,
  • Patient presenting a venous or mixed leg ulcer predominantly of venous origin (ABPI between ≥0.8≤1.3,
  • Leg ulcer presenting at least 3 inflammatory signs (e.g pain, erythema...)
  • Target leg ulcer located at least 3 cm from the edge of another wound.

Exclusion Criteria

  • Pregnant or breastfeeding patient,
  • Patient already participating in another clinical trial, except observational trial
  • Patient with epifascial arterial bypass (superficial arterial bypass)
  • Patient suffering from phlegmatia coerulea dolens, septic phlebitis, acute deep vein thrombosis (DVT), defined as the first 10 days from onset of symptoms, or any DVT for which compression is considered by the Investigator to be contraindicated.
  • Patient receiving or having received systemic antibiotics within the ten days prior to inclusion in the investigation, regardless of therapeutic class or indication,
  • Cancerous wound.

Arms & Interventions

Vashe solution

Experimental

Vashe solution is a wound irrigation solution that contain hypochlorous acid

Intervention: Vashe solution (Device)

Saline solution

Active Comparator

Saline solution is an isotonic solution designed for irrigation purposes of wounds

Intervention: Saline solution (Device)

Outcomes

Primary Outcomes

clinical success at week 4

Time Frame: week 4

Clinical success at Week 4, defined as a clinical score ≤ 1.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials